Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

AHA Scientific Sessions 2022

5-7 November 2022, Chicago, IL + Virtual

ORION-3: 4-year data with inclisiran

ORION-3: 4-year data with inclisiran

News from the American Heart Association Scientific Sessions 2022 Results from ORION-3, the 4-year open-label extension of the ORION-1 trial (1), showed sustained reduction in LDL cholesterol levels with a favourable safety profile. ORION-1 (ClinicalTrials.gov, NCT02597127) randomized 501 subjects with atherosclerotic cardiovascular disease (ASCVD) or…

read more »
OCEAN(a)-DOSE: Olpasiran shows substantial lipoprotein(a) reduction

OCEAN(a)-DOSE: Olpasiran shows substantial lipoprotein(a) reduction

News from the American Heart Association Scientific Sessions 2022 In the OCEAN(a)-DOSE trial, treatment with olpasiran, a small interfering RNA (siRNA) agent targeting apolipoprotein(a), reduced lipoprotein(a) [Lp(a)] by up to 100%. The study was simultaneously published in the New England Journal of Medicine (1). In…

read more »